EVGN — Evogene Income Statement
0.000.00%
- $30.35m
- $32.17m
- $5.64m
- 18
- 14
- 46
- 15
Annual income statement for Evogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.753 | 1.04 | 0.93 | 1.68 | 5.64 |
Cost of Revenue | |||||
Gross Profit | 0.419 | 0.466 | -5.55 | -4.75 | -2.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 21.9 | 25.9 | 31.9 | 32.1 | 32.1 |
Operating Profit | -21.2 | -24.8 | -31 | -30.4 | -26.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.1 | -26.2 | -30.4 | -29.8 | -26 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.1 | -26.2 | -30.4 | -29.8 | -26 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -18.1 | -23.4 | -27.8 | -26.6 | -23.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.1 | -23.4 | -27.8 | -26.6 | -23.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.7 | -0.83 | -0.686 | -0.644 | -0.523 |
Dividends per Share |